A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants
CONCLUSIONS: We determined the class and proportion of reclassified BRCA variants. In conclusion, reviews are required to provide clinical guidance, such as determining treatment direction and preventive measures in the future.PMID:38623660 | DOI:10.7754/Clin.Lab.2023.230911 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Jin Ju Kim Dong Ja Kim Eon Jeong Nam Kyung Eun Song Ji Yeon Ham Yu Kyung Kim Nan Young Lee Source Type: research
Highlights in metastatic breast cancer from the 2023 San Antonio Breast Cancer Symposium
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 1(1):1-16.NO ABSTRACTPMID:38625028 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 16, 2024 Category: Cancer & Oncology Source Type: research
Highlights in metastatic breast cancer from the 2023 San Antonio Breast Cancer Symposium: commentary
Clin Adv Hematol Oncol. 2024 Feb;22 Suppl 1(1):13-15.NO ABSTRACTPMID:38625029 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Source Type: research
Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know
Clin Breast Cancer. 2024 Mar 13:S1526-8209(24)00077-6. doi: 10.1016/j.clbc.2024.03.004. Online ahead of print.ABSTRACTNeoadjuvant systemic therapy (NST) was initially reserved for unresectable patients however it has been increasingly used to facilitate breast conservation, downstage the axilla, and inform adjuvant therapy decisions based on response. For patients with HER2+ and triple-negative breast cancer (TNBC), clinical trials have resulted in the ability to individualize treatment regimens. For HER2+ breast cancer, de-escalation of neoadjuvant regimens to minimize cytotoxic chemotherapy and de-escalation or escalatio...
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Stephanie Downs-Canner Anna Weiss Source Type: research
Plasma Thioredoxin Reductase as a Potential Diagnostic Biomarker for Breast Cancer
CONCLUSION: Plasma TrxR activity can be used as a suitable biomarker for breast cancer diagnosis and efficacy assessment.PMID:38616444 | DOI:10.1016/j.clbc.2024.03.008 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Yixuan Hu Yinxing Zhu Junfeng Shi Xiaowei Wei Cuiju Tang Xiaoxiang Guan Wenwen Zhang Source Type: research
Predictive medicine in a testis trio-family through a combined multi-omics approach
Clin Transl Med. 2024 Apr;14(4):e1643. doi: 10.1002/ctm2.1643.NO ABSTRACTPMID:38616705 | DOI:10.1002/ctm2.1643 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Federica Di Maggio Gianluca Damaggio Marcella Nunziato Silvia Buonaiuto Felice Crocetto Alessandra Calabrese Achille Aveta Gioacchino Vino Giacinto Donvito Savio Domenico Pandolfo Ciro Imbimbo Vincenza Colonna Francesco Salvatore Source Type: research
Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the prophylaxis and treatment of mild dermatitis induced by radiation therapy in breast cancer patients (the Alantel study)
CONCLUSIONS: The higher efficacy of Alantel® compared to the control cream in reducing the incidence of RD in women with breast cancer has been demonstrated.PMID:38616815 | PMC:PMC11010796 | DOI:10.1016/j.conctc.2024.101288 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: E Villegas-Becerril C Jimenez-Garcia L A Perula-de Torres M Espinosa-Calvo C M Bueno-Serrano F Romero-Ruperto F Gines-Santiago M C Moreno-Manzanaro J J Mu ñoz-Gavilan G Montes-Redondo M A Quesada-Roman M C Linares-Ramirez J M Parras-Rejano N Mu ñoz-Alca Source Type: research
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon
J Pathol Clin Res. 2024 Mar;10(2):e12361. doi: 10.1002/2056-4538.12361.ABSTRACTInvasive lobular carcinoma (ILC) is a special breast cancer type characterized by noncohesive growth and E-cadherin loss. Focal activation of P-cadherin expression in tumor cells that are deficient for E-cadherin occurs in a subset of ILCs. Switching from an E-cadherin deficient to P-cadherin proficient status (EPS) partially restores cell-cell adhesion leading to the formation of cohesive tubular elements. It is unknown what conditions control EPS. Here, we report on EPS in ILC metastases in the large bowel. We reviewed endoscopic colon biopsie...
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Malte Gronewold Isabel Grote Stephan Bartels Henriette Christgen Leonie D Kandt Maria Jose Brito G àbor Cserni Maximilian E Daemmrich Franz Fogt Burkhard M Helmke Natalie Ter Hoeve Corinna Lang-Schwarz Michael Vieth Axel Wellmann Elna Kuehnle Ulf Kulik G Source Type: research
Current status and prospects of artificial intelligence in breast cancer pathology: convolutional neural networks to prospective Vision Transformers
Int J Clin Oncol. 2024 Apr 15. doi: 10.1007/s10147-024-02513-3. Online ahead of print.ABSTRACTBreast cancer is the most prevalent cancer among women, and its diagnosis requires the accurate identification and classification of histological features for effective patient management. Artificial intelligence, particularly through deep learning, represents the next frontier in cancer diagnosis and management. Notably, the use of convolutional neural networks and emerging Vision Transformers (ViT) has been reported to automate pathologists' tasks, including tumor detection and classification, in addition to improving the effici...
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Ayaka Katayama Yuki Aoki Yukako Watanabe Jun Horiguchi Emad A Rakha Tetsunari Oyama Source Type: research
Organizational Breast Cancer Data Mart: A Solution for Assessing Outcomes of Imaging and Treatment
CONCLUSION: Institutional real-world data marts enable comprehensive understanding of care outcomes within an organization. As clinical data sources become increasingly structured, such marts may be an important source for future interinstitution analysis and potentially an opportunity to create robust real-world results that could be used to support evidence-based national policy and care decisions for breast cancer.PMID:38621193 | DOI:10.1200/CCI.23.00193 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Margarita L Zuley Jonathan Silverstein Durwin Logue Richard S Morgan Rohit Bhargava Priscilla F McAuliffe Adam M Brufsky Andriy I Bandos Robert M Nishikawa Source Type: research
Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know
Clin Breast Cancer. 2024 Mar 13:S1526-8209(24)00077-6. doi: 10.1016/j.clbc.2024.03.004. Online ahead of print.ABSTRACTNeoadjuvant systemic therapy (NST) was initially reserved for unresectable patients however it has been increasingly used to facilitate breast conservation, downstage the axilla, and inform adjuvant therapy decisions based on response. For patients with HER2+ and triple-negative breast cancer (TNBC), clinical trials have resulted in the ability to individualize treatment regimens. For HER2+ breast cancer, de-escalation of neoadjuvant regimens to minimize cytotoxic chemotherapy and de-escalation or escalatio...
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Stephanie Downs-Canner Anna Weiss Source Type: research
Plasma Thioredoxin Reductase as a Potential Diagnostic Biomarker for Breast Cancer
CONCLUSION: Plasma TrxR activity can be used as a suitable biomarker for breast cancer diagnosis and efficacy assessment.PMID:38616444 | DOI:10.1016/j.clbc.2024.03.008 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Yixuan Hu Yinxing Zhu Junfeng Shi Xiaowei Wei Cuiju Tang Xiaoxiang Guan Wenwen Zhang Source Type: research
Predictive medicine in a testis trio-family through a combined multi-omics approach
Clin Transl Med. 2024 Apr;14(4):e1643. doi: 10.1002/ctm2.1643.NO ABSTRACTPMID:38616705 | DOI:10.1002/ctm2.1643 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Federica Di Maggio Gianluca Damaggio Marcella Nunziato Silvia Buonaiuto Felice Crocetto Alessandra Calabrese Achille Aveta Gioacchino Vino Giacinto Donvito Savio Domenico Pandolfo Ciro Imbimbo Vincenza Colonna Francesco Salvatore Source Type: research
Efficacy of an aloe vera, chamomile, and thyme cosmetic cream for the prophylaxis and treatment of mild dermatitis induced by radiation therapy in breast cancer patients (the Alantel study)
CONCLUSIONS: The higher efficacy of Alantel® compared to the control cream in reducing the incidence of RD in women with breast cancer has been demonstrated.PMID:38616815 | PMC:PMC11010796 | DOI:10.1016/j.conctc.2024.101288 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 15, 2024 Category: Cancer & Oncology Authors: E Villegas-Becerril C Jimenez-Garcia L A Perula-de Torres M Espinosa-Calvo C M Bueno-Serrano F Romero-Ruperto F Gines-Santiago M C Moreno-Manzanaro J J Mu ñoz-Gavilan G Montes-Redondo M A Quesada-Roman M C Linares-Ramirez J M Parras-Rejano N Mu ñoz-Alca Source Type: research
The Modified Neo-Bioscore System for Staging Breast Cancer Treated with Neoadjuvant Therapy Based on Prognostic Significance of HER2-Low Expression
Conclusions: This study demonstrated that HER2-low tumor may exhibit prognostic significance. The innovative mNeo-Bioscore, based on a new classification of HER2 status, may serve as a prognostic staging system superior to Neo-Bioscore.PMID:38610617 | PMC:PMC11012268 | DOI:10.3390/jcm13071850 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Yingying Zhao Xinru Chen Yaohui Wang Xueqing Zhang Jingsong Lu Wenjin Yin Source Type: research
